SCHEMBL30794603

SCHEMBL30794603

Cc1c(C(=O)NCc2ccc(F)cc2)c(C2CC2)nc2cc(C(F)(F)F)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KCNQ3 O43525 1/20 0.43
KCNQ2 O43526 1/20 0.43
PTGER4 P35408 1/20 0.42
TACR1 P25103 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41
RECQL P46063 1/20 0.41
RAB9A P51151 1/20 0.41
MCL1 Q07820 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CTNNB1 P35222 4/20 0.41
TCF7L2 Q9NQB0 4/20 0.41
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22677 1.00 HTT (0.43) HTTSMN1; SMN2KCNQ3KCNQ2PTGER4
SCHEMBL30795823 0.96 SMN1; SMN2 (0.42) HTTSMN1; SMN2KCNQ3KCNQ2PTGER4
SCHEMBL22560 0.96 SMN1; SMN2 (0.42) HTTSMN1; SMN2KCNQ3KCNQ2PTGER4
SCHEMBL21363 0.90 CCR1 (0.42) TACR1MEN1KMT2AGAATSHR
SCHEMBL30795932 0.90 CCR1 (0.42) TACR1MEN1KMT2AGAATSHR
SCHEMBL22261 0.87 CCR1 (0.41) TACR1MEN1KMT2ALMNAALDH1A1
SCHEMBL30796283 0.87 CCR1 (0.41) TACR1MEN1KMT2ALMNAALDH1A1
SCHEMBL21069 0.87 HTT (0.44) HTTSMN1; SMN2KCNQ3KCNQ2MEN1
SCHEMBL30795612 0.87 HTT (0.44) HTTSMN1; SMN2KCNQ3KCNQ2MEN1
SCHEMBL21261 0.84 CTNNB1 (0.47) HTTSMN1; SMN2KCNQ3KCNQ2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed